Disease-modifying antirheumatic drug use in the treatment of juvenile idiopathic arthritis: a cross-sectional analysis of the CARRA Registry. - Wikidata - awgldk - TriplyDB

Disease-modifying antirheumatic drug use in the treatment of juvenile idiopathic arthritis: a cross-sectional analysis of the CARRA Registry.

Disease-modifying antirheumatic drug use in the treatment of juvenile idiopathic arthritis: a cross-sectional analysis of the CARRA Registry.

http://www.wikidata.org/entity/Q37147226

about

Treatment of juvenile idiopathic arthritis: a revolution in care Effectiveness and long-term retention of anti-tumour necrosis factor treatment in juvenile and adult patients with juvenile idiopathic arthritis: data from Reuma.pt.The new Childhood Arthritis and Rheumatology Research Alliance (CARRA) registry: design, rationale, and characteristics of patients enrolled in the first 12 months A survey of national and multi-national registries and cohort studies in juvenile idiopathic arthritis: challenges and opportunities Efficacy of adalimumab in young children with juvenile idiopathic arthritis and chronic uveitis: a case series Gut microbiome in children with enthesitis-related arthritis in a developing country and the effect of probiotic administration.Attitudes and Approaches for Withdrawing Drugs for Children with Clinically Inactive Nonsystemic JIA: A Survey of the Childhood Arthritis and Rheumatology Research Alliance.Seeking insights into the EPidemiology, treatment and Outcome of Childhood Arthritis through a multinational collaborative effort: Introduction of the EPOCA study.Treatment of patients with juvenile idiopathic arthritis (JIA) in a population-based cohort.Current perspectives on ophthalmic manifestations of childhood rheumatic diseases Using registries to identify adverse events in rheumatic diseases.The risk of hospitalized infection following initiation of biologic agents versus methotrexate in the treatment of juvenile idiopathic arthritis.Outcomes research in childhood autoimmune diseases.Infectious complications in juvenile idiopathic arthritis.Optimizing treatment in paediatric rheumatology--lessons from oncology.MISS questionnaire in French version: a good tool for children and parents to assess methotrexate intolerance.Use of Tumor Necrosis Factor-Alpha Inhibitors in Children and Young Adults With Juvenile Idiopathic Arthritis or Rheumatoid Arthritis.Methotrexate-induced nausea in the treatment of juvenile idiopathic arthritis.The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort.US trends in rates of arthroplasty for inflammatory arthritis including rheumatoid arthritis, juvenile idiopathic arthritis, and spondyloarthritis.Novel method to collect medication adverse events in juvenile arthritis: results from the childhood arthritis and rheumatology research alliance enhanced drug safety surveillance project.Safety of weekly adalimumab in the treatment of juvenile idiopathic arthritis and pediatric chronic uveitis.Children with juvenile idiopathic arthritis frequently experience interruptions to their medical therapy.Juvenile Spondyloarthropathies.

P2860

Q26849497-7E66C49A-AFF8-48F3-A400-29094957F712 Q31032345-0346E5D5-97BE-479A-8D95-51724C667BE4 Q33568429-791AD47F-E6CA-41C0-A79D-8F9582337095 Q33576975-334B3CE9-79E2-4F1D-A5F8-F56FE85604FF Q33712570-3C5A7E42-48E8-4B72-8023-38438FE0D074 Q36197744-2A7272C9-35E1-42A5-833D-9827FF576177 Q36266841-D9E4A98D-4339-4A54-9927-27626CCEC0C6 Q36552356-FEB031B7-488B-45E9-BBB1-94456A1EB878 Q36909288-A2B9C33C-3077-432A-B6E0-923F98A8F31A Q37007652-7C60AE9E-A81B-402E-9957-47B01489E82A Q37268816-92205B38-9563-4A98-A83B-B4D0B5AA3289 Q37274470-27717264-B374-4791-A8CB-BFF7495FCB9B Q37608011-D99773F8-B18F-475A-946A-F7E2F31EF537 Q38093095-1384E1E4-267B-4E0F-944F-00EBBBA01D98 Q38434311-E348BDB5-4136-4658-A191-2BECCA341A84 Q38801158-EDD4363F-A9C3-40FD-9CC1-C5D993117B7C Q38805990-C6B72E6A-128F-44C9-9A9C-E2754ED4D2CA Q39383677-98C41AE9-B2B4-4AE3-B09E-65942CAAEB0E Q44646094-9FD9651E-DD54-4275-A166-0A0CCC038C72 Q45247787-E934E8DC-40CF-47BE-BA87-E0121B5D8DBA Q45818093-A0D55068-1C40-40FA-BB4B-D53981302B9D Q47226473-7C15052B-6ED1-4759-BA4B-EA5DB57EBF7D Q48544610-75BC7EF5-AB25-49AA-A60C-E309AC9B79C6 Q51648725-F082B6C7-A6A5-432E-81F9-D0F63528FA8A

P2860

Disease-modifying antirheumatic drug use in the treatment of juvenile idiopathic arthritis: a cross-sectional analysis of the CARRA Registry.

http://www.wikidata.org/entity/Q37147226

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on August 2012

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Disease-modifying antirheumati ...... nalysis of the CARRA Registry.

@en

Disease-modifying antirheumati ...... nalysis of the CARRA Registry.

@nl

type

label

Disease-modifying antirheumati ...... nalysis of the CARRA Registry.

@en

Disease-modifying antirheumati ...... nalysis of the CARRA Registry.

@nl

prefLabel

Disease-modifying antirheumati ...... nalysis of the CARRA Registry.

@en

Disease-modifying antirheumati ...... nalysis of the CARRA Registry.

@nl

P1433

Q37147226-D2FBBD4B-0E35-4553-959B-D5122D7721E0

P1476

Q37147226-C2C01C16-EB49-4DE0-B12E-E4DFC13D4C66

P2093

Q37147226-52D11174-1FD7-46CC-B0AE-F00EC1A796C5

Q37147226-530AC7D2-629F-408F-9A9A-35502D5CFAFF

Q37147226-675932AA-A898-44D1-BF96-AE1AB61EBE75

Q37147226-6BCFA1D4-A62F-4927-AA90-737F00B55A9D

Q37147226-808325CB-6478-4216-9547-F936B994A94A

Q37147226-8D313804-E748-4F8C-A6A4-DA9419B32BD1

Q37147226-D47612E6-E653-4B9A-8161-0A2369908027

Q37147226-DB0B2BE5-647E-424B-9744-DC6532265AE1

P2860

Q37147226-2356CE0C-1885-43A0-862E-FC94C29D2766

Q37147226-28E9F139-BAF3-408A-B90E-9A2AF94A9542

Q37147226-3E39A646-4EA8-4557-AD73-0B649398D3CB

Q37147226-4B4112D4-8615-4610-A5DC-4656FE661D6D

Q37147226-4F078D65-CE5A-4BEF-BB1A-566F0E7C5CFA

Q37147226-50C45F63-2286-4D8F-AD4B-319B9E709DFE

Q37147226-51D165DE-22E0-4433-84D7-51BB4BF5BC49

Q37147226-73F82356-F53F-4597-B7A1-586B627218A2

Q37147226-76B1B348-FA1B-448B-8093-30060D49E0BB

Q37147226-831DABF8-A2CE-4DCD-9DB1-8B0768D3084B

P304

Q37147226-017C7617-C096-43F1-A89F-10B16179B6FF

P31

Q37147226-8A387174-736E-4E0C-A32D-BA4D8EEE8354

P356

Q37147226-61054619-9F66-48DF-AA34-12AC2BD2DD46

P407

Q37147226-93E40F38-622D-404E-A9CF-68BA11940F06

P433

Q37147226-961AEA86-FBD4-42D8-8F45-65710873EE47

P478

Q37147226-8782BFEB-3CA4-419C-A6DE-4B9C96A17B23

P577

Q37147226-25E9C3A8-4507-447F-ABF8-4F6D8B2346F3

P698

Q37147226-C623E4C0-902A-48F2-BC0B-43101DF0A7A5

P921

Q37147226-3005D2D4-3A8B-467B-95BC-0277CEECC506

P932

Q37147226-8B3E28FB-803A-451A-B2A4-7583CF4342F7

P356

P1433

The Journal of Rheumatology

P1476

Disease-modifying antirheumati ...... nalysis of the CARRA Registry.

@en

P2093

CARRA Registry Investigators

http://www.w3.org/2001/XMLSchema#string

Christina F Pelajo

http://www.w3.org/2001/XMLSchema#string

Esi Morgan DeWitt

http://www.w3.org/2001/XMLSchema#string

Pamela F Weiss

http://www.w3.org/2001/XMLSchema#string

Sarah Ringold

http://www.w3.org/2001/XMLSchema#string

Timothy Beukelman

http://www.w3.org/2001/XMLSchema#string

Trevor E Davis

http://www.w3.org/2001/XMLSchema#string

Yukiko Kimura

http://www.w3.org/2001/XMLSchema#string

P2860

International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001

Adalimumab with or without methotrexate in juvenile rheumatoid arthritis.

Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension.

Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial.

A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)

Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial.

2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features.

ASAS/EULAR recommendations for the management of ankylosing spondylitis.

Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis.

Adalimumab in the therapy of uveitis in childhood

P304

1867-1874

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3899/JRHEUM.120110

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

39

http://www.w3.org/2001/XMLSchema#string

P577

2012-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22859354

http://www.w3.org/2001/XMLSchema#string

P921

juvenile rheumatoid arthritis

P932

3763075

http://www.w3.org/2001/XMLSchema#string